Remove 2026 Remove Bioethics Remove Diabetes
article thumbnail

Bayer Pharmaceuticals accelerates innovations for patients

LifeProNow

Kerendia is already approved in major markets in chronic kidney disease (CKD) associated with type 2 diabetes. billion in sales by 2026. Bayer works on leveraging all the possibilities of the technologies while fully integrating all regulatory and bioethical requirements.”

Bioethics 130